SV

Street Verdict

Analyst Scorecard

POLYMED · NSE

Poly Medicure Limited

₹1,726

+0.78% (+₹13.3)

Prev. close

₹1,712.7

Volume

1,50,328

Delivery %

42.0%

As of

18 Sept 2026

Price history

Bullish

Vishnu Kant Upadhyay · Master Capital Services · 11 Aug 2026

“Bullish on Poly Medicure for the near term, targeting ₹1,900 and ₹1,950, with a stop loss at ₹1,665. The stock is showing a potential trend reversal with a decisive breakout above the ₹1,700 resistance zone on high volumes, forming higher highs and higher lows, and reclaiming key moving averages.”

Entry ≈ ₹1,863.9 (first trade after call)Target ₹1,900 (+1.9%)Stop ₹1,665 (-10.7%)R:R ~0.2:1Target hit · 12 Aug 2026

Published mid-session at 10:00 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.

Target ₹1,900NOT GRADEDCall pageClear
₹1,726-₹137.9 (-7.40%) · CALL
11 Aug 2026 → 18 Sept 2026
Target ₹1,900SL ₹1,665Entry ₹1,863.911 Aug21 Aug31 Aug09 Sept18 SeptCall published 10:00
Vishnu Kant Upadhyay's call · 11 Aug 2026

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in window

Commentary

none in window

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
“Bullish on Poly Medicure for the near term, targeting ₹1,900 and ₹1,950, with a stop loss at ₹1,665. The stock is showin…”Vishnu Kant UpadhyayMaster Capital ServicesPoly MedicureNOT GRADED
“Bullish on Poly Medicure for the near term, targeting ₹1,900 and ₹1,950, with a stop loss at ₹1,665. The stock is showing a potential trend reversal with a decisive breakout above the ₹1,700 resistance zone on high volumes, forming higher highs and higher lows, and reclaiming key moving averages.”
Trade setupTarget ₹1,900Track opinion →

This call couldn't be objectively graded against market data.

Read the original article

Fundamentals

About Poly Medicure Limited

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA balloon dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, including blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, and foley balloon and urine drainage catheters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.

Details

Sector

Healthcare

Industry

Medical Instruments & Supplies

CEO

Mr. Himanshu Baid

Headquarters

New Delhi

Employees

2,614

Key stats

Market cap

₹17,494.99 Cr

P/E ratio (TTM)

55.7

Dividend yield

0.20%

EPS (TTM)

₹31.00

Beta (1Y · daily vs NIFTY 50)

0.95

Beta (5Y · monthly vs NIFTY 50)

0.85

Shares float

3.63 Cr

EPS · quarter ended Jun 2026

₹8.48

Financial Performance

01 · Financials

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0%10%20%30%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.6% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

010203040₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

01234₹-200%0%200%400%27 Feb 2016 Sept 2116 Sept 2221 Sept 2319 Sept 2418 Sept 2528 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

0%20%40%60%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-200 Cr0 Cr200 Cr400 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹786.47 Cr₹923.06 Cr₹1,115.23 Cr₹1,375.80 Cr₹1,669.83 Cr₹1,875.26 Cr
EBITDA₹232.78 Cr₹251.00 Cr₹301.57 Cr₹416.97 Cr₹547.69 Cr₹561.28 Cr
₹135.87 Cr₹146.51 Cr₹179.28 Cr₹258.26 Cr₹338.56 Cr₹331.29 Cr
Diluted EPS₹15.24₹15.27₹18.67₹26.9₹34.11₹31.75

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,223.73 Cr₹1,376.83 Cr₹1,577.21 Cr₹1,858.67 Cr₹3,192.45 Cr₹3,918.57 Cr
₹137.43 Cr₹126.71 Cr₹149.02 Cr₹173.90 Cr₹180.25 Cr₹353.58 Cr
Stockholders' equity₹965.57 Cr₹1,087.48 Cr₹1,241.63 Cr₹1,470.05 Cr₹2,765.66 Cr₹3,106.17 Cr

Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹118.73 Cr₹123.47 Cr₹190.83 Cr₹266.08 Cr₹233.05 Cr₹246.37 Cr
Investing cash flow₹-435.58 Cr₹-85.33 Cr₹-179.02 Cr₹-240.94 Cr₹-1,191.17 Cr₹-225.38 Cr
₹316.95 Cr₹-35.34 Cr₹-12.51 Cr₹-20.15 Cr₹952.93 Cr₹20.15 Cr
Capital expenditure₹-95.13 Cr₹-155.58 Cr₹-239.27 Cr₹-277.02 Cr₹-331.03 Cr₹-308.39 Cr
End cash position₹4.95 Cr₹7.76 Cr₹7.06 Cr₹12.05 Cr₹8.70 Cr₹51.23 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21Mar 22Jun 22Sep 22–Dec 22(2Q)Mar 23–Jun 23(2Q)Sep 23–Dec 23(2Q)Mar 24Jun 24Aug 24–Sep 24(2Q)Dec 24–Jun 25(3Q)Sep 25–Jun 26(4Q)
Promoter44.77%44.76%44.66%53.34%53.33%53.31%53.16%53.15%66.03%62.56%62.44%62.42%
Public55.23%55.24%55.34%46.66%46.67%46.69%46.84%46.85%33.97%37.44%37.56%37.58%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Poly Medicure Limited₹17,360.18 Cr₹1,72655.25.5910.7%0.11+12.3%-16.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 28

Concall transcripts

Show all 11

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

21 indices

Nifty MidSmall Healthcare· 1.0%Nifty Smallcap250 Momentum Quality 100· 0.6%Nifty500 Healthcare· 0.4%BSE Healthcare· 0.4%BSE 250 SmallCap Index· 0.3%Nifty Smallcap 500· 0.2%Nifty MidSmallcap 400· 0.1%Nifty MidSmallcap400 50:50· 0.1%BSE 400 MidSmallCap Index· 0.1%Nifty 500· 0.0%Nifty500 Equal Weight· 0.0%Nifty500 LargeMidSmall Equal-Cap Weighted· 0.0%

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

POLYMED

Poly Medicure: Final Dividend Record Date Set for August 29, 2026

InvestyWise · 1 month ago

POLYMED

Poly Medicure Q1 results: Net profit falls 8% YoY to Rs 85.3 crore, revenue up 30%

Poly Medicure Ltd. reported an 8.3% year-on-year decline in Q1 net profit to ₹85.3 crore. This occurred despite a 30.3% increase in revenue to ₹525 crore and a 17.9% rise in EBITDA. The company's EBITDA margin decreased to 23.8% from 26.3% in the same period last year.

1 month ago·Read at Business Upturn